Philippe JEAN-PIERRE

---

• Type de publi. :
• Date de publi. : 01/08/2023
• Auteurs : Andreas BikfalviCristine Alves da CostaTony AvrilJean-Vianney BarnierLuc BauchetLucie BrissonPierre-François CartronHélène CastelÉric ChevetHerve ChneiweissAnne ClavreulBruno ConstantinValérie CoronasThomas DaubonMonique DontenwillFrancois DucrayNatacha Entz-WerléDominique Figarella-BrangerIsabelle FournierJean-Sébastien FrenelM. GabutThierry GalliJulie GavardGilles HuberfeldJean-Philippe HugnotAhmed IdbaihMarie-Pierre JunierThomas MathivetPhilippe MeneiDavid MeyronetCéline MirjoletFabrice MorinJean MosserElizabeth Cohen-Jonathan MoyalVéronique RousseauMichel SalzetMarc SansonGiorgio SeanoEmeline TabouretAurelie TchoghandjianLaurent TurchiFrancois ValletteSomya VatsMaité VerreaultThierry Virolle
• Organismes : Niche, Nutrition, Cancer et métabolisme oxydatif Centre de Recherche en Cancérologie et Immunologie Nantes-Angers Service de neurochirurgie [CHU Angers] Protéomique, Réponse Inflammatoire et Spectrométrie de Masse (PRISM) - U 1192 Centre de Recherche en Cancérologie de Lyon Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes-Angers Signaling in Oncogenesis, Angiogenesis and Permeability - SOAP Institut National de la Santé et de la Recherche Médicale Institut de Cancérologie de l'Ouest [Angers/Nantes] Centre National de la Recherche Scientifique Service de neurochirurgie [CHU Angers] Centre de Recherches en Cancérologie de Toulouse Oncopole Claudius Regaud Université Toulouse III - Paul Sabatier Université de Lille Protéomique, Réponse Inflammatoire et Spectrométrie de Masse (PRISM) - U 1192 Harvard Medical School [Boston] Massachusetts General Hospital [Boston] Institut Curie [Paris]
• Publié dans Trends in Cancer le 26/10/2020

---

Résumé : Abstract FET:CREB fusions have been described in a variety of tumors from various phenotypes. Recently, these fusion transcripts were reported in intracranial tumors, variably named intracranial mesenchymal myxoid tumors or angiomatoid fibrous histiocytomas. Controversy remains concerning the terminology for these tumors. Here, we report 11 cases of central nervous system mesenchymal tumors with proven FET:CREB fusion. Most DNA methylation profiles were not classifiable using the Heidelberg Brain Tumor or Sarcoma Classifier (v11b4/v12.2). However, by using unsupervised t‐SNE and hierarchical clustering analyses, six of the cases constituted a distinct cluster. The remaining four tumors showed no obvious relation to any of the other referenced classes but were close to the clusters of extra‐CNS angiomatoid fibrous histiocytomas (n = 1), clear cell sarcomas (n = 1), or solitary fibrous tumors (n = 2). Our findings confirm that intracranial FET:CREB‐fused tumors do not represent a single molecular tumor entity, although most samples clustered close to each other, indicating the existence of a distinct epigenetic group that could potentially be partially masked by the low number of cases included. Further analyses are needed to characterize intracranial FET:CREB fused‐defined tumors in more detail.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/08/2023
• Auteurs : Victor WaldmannChristelle MarquiéFrancis BessièreDavid PerrotFrédéric AnselmeNicolas BadencoSergio BarraGéraldine BertauxHugues BlangyPierre BordacharSerge BovedaMichel ChauvinNicolas ClémentyGaël ClericiNicolas CombesPascal DefayeJean-Claude DeharoPhilippe DurandGuillaume DuthoitRomain EschalierLaurent FauchierRodrigue GarciaOlivier GeoffroyEdouard GitenayJean-Baptiste GourraudCharles GuenanciaLaurence IserinPeggy JaconLaurence Jesel-MorelFawzi KerkouriDidier KlugLinda KoutbiFabien LabombardaMagalie LadouceurGabriel LaurentChristophe LeclercqBaptiste MailleAlice MaltretGrégoire MassouliéPierre MondolySandro NinniPierre OllitraultJean-Luc PasquiéBertrand PierrePénélope PujadasLaure Champ-RigotFrédéric SacherNicolas SadoulAlexandre SchatzPierre WinumPaul-Ursmar MilliezVincent ProbstEloi Marijon
• Organismes : Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research Laboratoire Traitement du Signal et de l'Image Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] Centre Hospitalier Régional Universitaire [Montpellier]
• Publié dans Journal of the American College of Cardiology le 26/10/2020

---

Fichiers liés : 2023 Waldmann et al., Subcutaneous.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/08/2023
• Auteurs : Astrid Boulenger de HauteclocqueLoic FerrerDamien AmbrosettiSolene RicardPierre BigotKarim BensalahFrançois HenonNicolas DoumercArnaud MéjeanVirginie VerkarreCharles DarianeStéphane LarréCécile Maud ChampyAlexandre de La TailleFranck BruyèreMorgan RoupretPhilippe PaparelStéphane DroupyAlexis FontenilJean-Jacques PatardXavier DurandThibaut WaeckelHervé LangCédric LebacleLaurent GuyGéraldine PignotMatthieu DurandJean-Alexandre LongThomas CharlesÉvanguelos XylinasRomain BoissierMokrane YacoubThierry ColinJean-Christophe Bernhard
• Organismes : service d'urologie [CHU Bordeaux] SOPHiA GENETICS [Pessac] Centre Hospitalier Universitaire de Nice service d'urologie [CHU Bordeaux] Centre Hospitalier Universitaire d'Angers Service d'urologie [Rennes] = Urology [Rennes] Laboratoire Traitement du Signal et de l'Image Service d'Urologie, andrologie et transplantation rénale [CHRU Lille] Département d'Urologie-Andrologie et Transplantation Rénale [CHU Toulouse] Hôpital Européen Georges Pompidou [APHP] Hôpital Européen Georges Pompidou [APHP] Hôpital Européen Georges Pompidou [APHP] Hôpital universitaire Robert Debré [Reims] Hôpital Henri Mondor Hôpital Henri Mondor Service d'urologie [CHRU Tours] CHU Pitié-Salpêtrière [AP-HP] Service d'urologie [Centre Hospitalier Lyon Sud - HCL] Centre Hospitalier Universitaire de Nîmes Université de Montpellier Centre Hospitalier Universitaire de Nîmes Centre Hospitalier Intercommunal de Mont-de-Marsan et du pays des Sources [Landes] Imagerie Moléculaire et Stratégies Théranostiques Centre hospitalier Saint-Joseph [Paris] Service d'Urologie [CHU Caen] Service d'Urologie [Strasbourg] Hôpital Bicêtre [GHU AP-HP. Université Paris-Saclay, Le Kremlin-Bicêtre] Imagerie Moléculaire et Stratégies Théranostiques Service Urologie [CHU Clermont-ferrand] Institut Paoli-Calmettes Centre Hospitalier Universitaire de Nice Service d'urologie [CHU Grenoble] Service d'urologie [CHU de Poitiers] AP-HP - Hôpital Bichat - Claude Bernard [Paris] CHU Marseille Service de pathologie [Bordeaux] SOPHiA GENETICS [Pessac] service d'urologie [CHU Bordeaux]
• Publié dans BJU International le 28/10/2020

---

Résumé : Objectives: To assess the impact of pathological upstaging from clinically localized to locally advanced pT3a on survival in patients with renal cell carcinoma (RCC), as well as the oncological safety of various surgical approaches in this setting, and to develop a machine-learning-based, contemporary, clinically relevant model for individual preoperative prediction of pT3a upstaging. Materials and Methods: Clinical data from patients treated with either partial nephrectomy (PN) or radical nephrectomy (RN) for cT1/cT2a RCC from 2000 to 2019, included in the French multi-institutional kidney cancer database UroCCR, were retrospectively analysed. Seven machine-learning algorithms were applied to the cohort after a training/testing split to develop a predictive model for upstaging to pT3a. Survival curves for disease-free survival (DFS) and overall survival (OS) rates were compared between PN and RN after G-computation for pT3a tumours. Results: A total of 4395 patients were included, among whom 667 patients (15%, 337 PN and 330 RN) had a pT3a-upstaged RCC. The UroCCR-15 predictive model presented an area under the receiver-operating characteristic curve of 0.77. Survival analysis after adjustment for confounders showed no difference in DFS or OS for PN vs RN in pT3a tumours (DFS: hazard ratio [HR] 1.08, P = 0.7; OS: HR 1.03, P > 0.9). Conclusions: Our study shows that machine-learning technology can play a useful role in the evaluation and prognosis of upstaged RCC. In the context of incidental upstaging, PN does not compromise oncological outcomes, even for large tumour sizes.

---

Fichiers liés : BJU International - 2023 - Boulenger de Hauteclocque - Machine‐learning approach for prediction of pT3a upstaging and.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/08/2023
• Auteurs : Guillaume ChassagnonMostafa El HajjamSamia BoussouarMarie-Pierre RevelRalph KhouryBenoît GhayeSébastien BommartMathieu LederlinStephane Tran BaConstance de Margerie-MellonLaure FournierLucie CassagnesMickaël OhanaCarole JalaberGaël DournesNicolas CazeneuveGilbert Raymond FerrettiPauline TalabardVictoria DonciuEmma CanniffMarie-Pierre DebrayBernard CrutzenJérémy CharriotValentin RabeauPhilippe KhafagyRichard ChocronIan Leonard-LorantLoic MetairyLea Ruez-LantuejoulSebastien BeaunePierre HausfaterAnne‐laure PhilipponAntoine KhalilAndrea PenalozaThibaut AffolePierre Yves BrilletCatherine RoyJulien PucheuxJordan ZbiliOlivier SanchezRaphaël Porcher
• Organismes : Service de Radiologie [CHU Cochin] Université Paris Cité Hôpital Ambroise Paré [AP-HP] Université Paris-Saclay Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] Laboratoire d'Imagerie Biomédicale [Paris] Service de Radiologie [CHU Cochin] Université Paris Cité Département de Radiologie [Bichat] Université Paris Cité Cliniques Universitaires Saint-Luc [Bruxelles] Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] Hôpital Arnaud de Villeneuve [CHU Montpellier] Service de radiologie et imagerie médicale [Rennes] = Radiology [Rennes] Département de Radiologie [Rennes] Laboratoire Traitement du Signal et de l'Image Service de radiologie [Avicenne] Service de radiologie [Saint-Louis] Paris-Centre de Recherche Cardiovasculaire Service Imagerie Médicale et Radiologie Interventionnelle - site Gabriel-Montpied [CHU Clermont-Ferrand] Thérapie guidée par l'image Nouvel Hôpital Civil de Strasbourg Université de Strasbourg Service de Radiologie [CHU Saint-Etienne] Centre de recherche Cardio-Thoracique de Bordeaux [Bordeaux] Hôpital Haut-Lévêque [CHU Bordeaux] Centre Hospitalier Régional Universitaire de Tours BrainTech Laboratory [CHU Grenoble Alpes - Inserm U1205] Hôpital Ambroise Paré [AP-HP] Université Paris-Saclay CHU Pitié-Salpêtrière [AP-HP] Service de Radiologie [CHU Cochin] Université Paris Cité Département de Radiologie [Bichat] Université Paris Cité Cliniques Universitaires Saint-Luc [Bruxelles] Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] Département pneumologie et addictologie [Montpellier] Service de radiologie et imagerie médicale [Rennes] = Radiology [Rennes] Département de Radiologie [Rennes] Service de radiologie [Avicenne] Hôpital Européen Georges Pompidou [APHP] Nouvel Hôpital Civil de Strasbourg Centre Hospitalier Régional Universitaire de Tours CHU de Grenoble-Alpes - Centre Hospitalier Universitaire CHU Grenoble Hôpital Ambroise Paré [AP-HP] Université Paris-Saclay CHU Pitié-Salpêtrière [AP-HP] Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases Groupe de recherche clinique Biomarqueurs d’urgence et de réanimation Hôpital Cochin [AP-HP] Université Paris Cité Département de Radiologie [Bichat] Université Paris Cité Cliniques Universitaires Saint-Luc [Bruxelles] Service de radiologie et imagerie médicale [Rennes] = Radiology [Rennes] Département de Radiologie [Rennes] Service de radiologie [Avicenne] Hypoxie et Poumon : pneumopathologies fibrosantes, modulations ventilatoires et circulatoires Nouvel Hôpital Civil de Strasbourg Centre Hospitalier Régional Universitaire de Tours Service de radiologie et imagerie médicale [Rennes] = Radiology [Rennes] Département de Radiologie [Rennes] Hôpital Européen Georges Pompidou [APHP] Université Paris Cité Centre d'épidémiologie Clinique [Hôtel-Dieu] Université Paris Cité
• Publié dans European Radiology le 23/10/2020

---

Résumé : Objectives: The objective was to define a safe strategy to exclude pulmonary embolism (PE) in COVID-19 outpatients, without performing CT pulmonary angiogram (CTPA). Methods: COVID-19 outpatients from 15 university hospitals who underwent a CTPA were retrospectively evaluated. D-Dimers, variables of the revised Geneva and Wells scores, as well as laboratory findings and clinical characteristics related to COVID-19 pneumonia, were collected. CTPA reports were reviewed for the presence of PE and the extent of COVID-19 disease. PE rule-out strategies were based solely on D-Dimer tests using different thresholds, the revised Geneva and Wells scores, and a COVID-19 PE prediction model built on our dataset were compared. The area under the receiver operating characteristics curve (AUC), failure rate, and efficiency were calculated. Results: In total, 1369 patients were included of whom 124 were PE positive (9.1%). Failure rate and efficiency of D-Dimer > 500 μg/l were 0.9% (95%CI, 0.2-4.8%) and 10.1% (8.5-11.9%), respectively, increasing to 1.0% (0.2-5.3%) and 16.4% (14.4-18.7%), respectively, for an age-adjusted D-Dimer level. D-dimer > 1000 μg/l led to an unacceptable failure rate to 8.1% (4.4-14.5%). The best performances of the revised Geneva and Wells scores were obtained using the age-adjusted D-Dimer level. They had the same failure rate of 1.0% (0.2-5.3%) for efficiency of 16.8% (14.7-19.1%), and 16.9% (14.8-19.2%) respectively. The developed COVID-19 PE prediction model had an AUC of 0.609 (0.594-0.623) with an efficiency of 20.5% (18.4-22.8%) when its failure was set to 0.8%. Conclusions: The strategy to safely exclude PE in COVID-19 outpatients should not differ from that used in non-COVID-19 patients. The added value of the COVID-19 PE prediction model is minor.

---

Fichiers liés : 2023 Chassagnon et al Strategies to safely.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/08/2023
• Auteurs : Simon GalmicheBenjamin ThoreauStéphane BretagneAlexandre AlanioAndré PaugamSophie CassaingJean-Pierre GangneuxHélène GueganLoïc FavennecAlida MinozaFlorent MorioJulie BonhommeGuillaume DesoubeauxOdile EloyLilia HasseineMilène SassoLaurence MillonAnne-Pauline BellangerPhilippe PoirierMaxime MoniotTaieb ChouakiAntoine HugueninFrédéric DalleBernard BouteilleMuriel NicolasNicole Desbois-NogardMarie-Elisabeth BougnouxFrançois DanionVincent PoindronAntoine NéelKarine Boukris-SitbonFanny LanternierBenjamin TerrierThe French Mycoses Study GroupCéline Damiani
• Organismes : Epidémiologie des Maladies Emergentes - Emerging Diseases Epidemiology Institut Pierre Louis d'Epidémiologie et de Santé Publique Institut Cochin Hopital Saint-Louis [AP-HP] Centre National de Référence Mycoses Invasives et Antifongiques - National Reference Center Invasive Mycoses & Antifungals Hopital Saint-Louis [AP-HP] Centre National de Référence Mycoses Invasives et Antifongiques - National Reference Center Invasive Mycoses & Antifungals Hôpital Cochin [AP-HP] Service de Parasitologie et Mycologie [CHU Toulouse] Institut de recherche en santé, environnement et travail Institut de recherche en santé, environnement et travail Infections Respiratoires Fongiques SFR UA 4208 Interactions Cellulaires et Applications Thérapeutiques CHU Rouen Université de Rouen Normandie Université de Poitiers = University of Poitiers Centre hospitalier universitaire de Poitiers = Poitiers University Hospital Cibles et Médicaments des Infections et de l'Immunité - UR 1155 Centre Hospitalier Universitaire de Nantes = Nantes University Hospital CHU Caen Normandie – Centre Hospitalier Universitaire de Caen Normandie Aliments Bioprocédés Toxicologie Environnements Centre d’Etude des Pathologies Respiratoires [Tours] Centre Hospitalier Régional Universitaire de Tours CHU Nice [Cimiez] Maladies infectieuses et vecteurs : écologie, génétique, évolution et contrôle Centre Hospitalier Universitaire de Nîmes Laboratoire Chrono-environnement (UMR 6249) Service de parasitologie et mycologie [CHRU de Besançon] Service de parasitologie et mycologie [CHRU de Besançon] Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte CHU Clermont-Ferrand CHU Clermont-Ferrand CHU Amiens-Picardie Hôpital universitaire Robert Debré [Reims] Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand Procédés Alimentaires et Microbiologiques [Dijon] CHU Limoges CHU Pointe-à-Pitre / Abymes [Guadeloupe] Centre Hospitalier Universitaire de Martinique [Fort-de-France, Martinique] Unité de Parasitologie-Mycologie, Service de Microbiologie [Hôpital Necker-Enfants-Malades, Paris] Biologie et Pathogénicité fongiques - Fungal Biology and Pathogenicity Immuno-Rhumatologie Moléculaire Centre Hospitalier Universitaire [Strasbourg] Centre Hospitalier Universitaire [Strasbourg] Centre de Recherche en Transplantation et Immunologie - Center for Research in Transplantation and Translational Immunology Centre National de Référence Mycoses Invasives et Antifongiques - National Reference Center Invasive Mycoses & Antifungals Centre National de Référence Mycoses Invasives et Antifongiques - National Reference Center Invasive Mycoses & Antifungals Service des Maladies infectieuses et tropicales [CHU Necker] Hôpital Cochin [AP-HP] Paris-Centre de Recherche Cardiovasculaire Agents infectieux, résistance et chimiothérapie - UR UPJV 4294 French Mycoses Study Group
• Publié dans RMD Open le 12/11/2022

---

Résumé : Objectives We aimed to describe patients with autoimmune diseases (AID) developing invasive fungal disease (IFD) and identify factors associated with short-term mortality. Methods We analysed cases of IFD associated with AID from the surveillance network of invasive fungal diseases (Réseau de surveillance des infections fongiques invasives, RESSIF) registry of the French national reference centre for invasive mycoses. We studied association of AID-specific treatments with 30-day mortality. We analysed total lymphocyte and CD4-T cell counts in patients with Pneumocystis jirovecii pneumonia (PCP). Results From 2012 to 2018, 549 individuals with IFD and AID were included, mainly with PCP (n=227, 41.3%), fungemia (n=167, 30.4%) and invasive aspergillosis (n=84, 15.5%). Rheumatoid arthritis (RA) and anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitides (AAV) were the most frequent AID in PCP (n=55 and 25, respectively) and invasive aspergillosis (n=15 and 10, respectively), inflammatory bowel diseases (IBDs) were predominant in fungemia (n=36). At IFD diagnosis, 365 (66.5%) patients received glucocorticoids (GCs), 285 (51.9%) immunosuppressants, 42 (7.7%) tumor necrosis factor (TNF)-α blockers, 75 (13.7%) other biologics. Mortality at 30 days was 28.1% (143/508). Fungemia and high-dose GCs were independently associated with higher 30-day mortality. In PCP patients, lymphopenia <1500/mm 3 was frequent (132/179, 73.7%) even if CD4+T cell count exceeded 200/mm 3 in 56/78 patients (71.8%) (median 472.5/mm 3 , IQR 160–858). Conclusion IFD associated with AID occurs primarily in RA, AAV and IBD, especially when treated with GCs and immunosuppressants. Mortality is high, especially for patients on high-dose GCs. Lymphopenia may help identify risk of PCP, but normal CD4+T cell count does not rule out the risk. Further studies are needed to assess the individual risk factors for IFD.

---

Fichiers liés : rmdopen-2023-003281.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/08/2023
• Auteurs : Pierre-Louis DeclercqIsabelle FournelMatthieu DemeyereAnissa BerraiesEléa KsiazekMartine NyungaCédric DaubinAlexandre AmpereBertrand SauneufJulio BadieAgathe DelboveSaad NseirElise Artaud-MacariVanessa BironneauMichel RamakersJulien MaizelArnaud-Felix MiailheBéatrice LacombeNicolas DelbergheWalid OulehriHugues GeorgesXavier TchenioCaroline ClarotElise RedureauGaël BourdinLaura FedericiMélanie AddaDavid SchnellMehdi BoustaCharlotte Salmon GandonnièreThierry VanderlindenGaëtan PlantefeveDavid DelacourCyrille DelpierreGurvan Le BouarNicholas SedillotGaëtan BeduneauAntoine RivièreNicolas Meunier-BeillardStéphanie GélinotteJean-Philippe RigaudMarie LabruyèreMarjolaine GeorgesChristine BinquetJean-Pierre Quenot
• Organismes : Centre hospitalier de Dieppe Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand Centre d'Investigation Clinique 1432 (Dijon) - Epidemiologie Clinique/Essais Cliniques CHU Rouen Hôpitaux de Chartres [Chartres] Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand Centre d'Investigation Clinique 1432 (Dijon) - Epidemiologie Clinique/Essais Cliniques Centre Hospitalier de Roubaix CHU Caen Normandie – Centre Hospitalier Universitaire de Caen Normandie Centre Hospitalier de Béthune CH Centre Hospitalier Public du Cotentin Hôpital Nord Franche-Comté [Hôpital de Trévenans] Centre hospitalier Bretagne Atlantique (Morbihan) Hôpital Roger Salengro [Lille] Unité de Glycobiologie Structurale et Fonctionnelle - UMR 8576 Groupe de Recherche sur le Handicap Ventilatoire CHU Rouen Centre hospitalier universitaire de Poitiers = Poitiers University Hospital CIC de Poitiers – Centre d'investigation clinique de Poitiers (CIC 1402) Centre Hospitalier Mémorial France États-Unis de Saint-Lô CHU Amiens-Picardie Mécanismes physiopathologiques et conséquences des calcifications cardiovasculaires - UR UPJV 7517 Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Groupe Hospitalier Bretagne Sud Centre Hospitalier Eure-Seine - Hôpital d'Evreux et de Vernon Centre Hospitalier Universitaire [Strasbourg] Centre Hospitalier Tourcoing Centre Hospitalier Fleyriat [Bourg en Bresse] Centre Hospitalier d'Abbeville Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon Centre hospitalier Saint Joseph - Saint Luc [Lyon] Hôpital Louis Mourier - AP-HP [Colombes] Hôpital Nord [CHU - APHM] Centre Hospitalier d'Angoulême Groupe Hospitalier du Havre Centre Hospitalier Régional Universitaire de Tours Hôpital Saint Philibert [Lomme] Experience ; Technology & Human Interactions ; Care & Society : Centre hospitalier Victor Dupouy [Centre hospitalier d'Argenteuil] Clinique du Cèdre Equipe EQUITY (CERPOP) Centre Hospitalier Eure-Seine - Hôpital d'Evreux et de Vernon Centre Hospitalier Fleyriat [Bourg en Bresse] CHU Rouen Groupe de Recherche sur le Handicap Ventilatoire et Neurologique Centre Hospitalier d'Abbeville Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand Centre d'Investigation Clinique 1432 (Dijon) - Epidemiologie Clinique/Essais Cliniques Centre hospitalier de Dieppe Centre hospitalier de Dieppe CHU Caen Normandie – Centre Hospitalier Universitaire de Caen Normandie Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand Laboratoire d'Excellence : Lipoprotéines et Santé : prévention et Traitement des maladies Inflammatoires et du Cancer Lipides et transfert des lipides dans l'inflammation et le sepsis (CTM UMR 1231) Centre d'Investigation Clinique 1432 (Dijon) - Epidemiologie Clinique/Essais Cliniques Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand Centre d'Investigation Clinique 1432 (Dijon) - Epidemiologie Clinique/Essais Cliniques Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand Lipides et transfert des lipides dans l'inflammation et le sepsis (CTM UMR 1231) Centre d'Investigation Clinique 1432 (Dijon) - Epidemiologie Clinique/Essais Cliniques
• Publié dans Intensive Care Medicine le 27/10/2020

---

Résumé : Purpose: Survivors after acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19) are at high risk of developing respiratory sequelae and functional impairment. The healthcare crisis caused by the pandemic hit socially disadvantaged populations. We aimed to evaluate the influence of socio-economic status on respiratory sequelae after COVID-19 ARDS.Methods: We carried out a prospective multicenter study in 30 French intensive care units (ICUs), where ARDS survivors were pre-enrolled if they fulfilled the Berlin ARDS criteria. For patients receiving high flow oxygen therapy, a flow ≥ 50 l/min and an FiO2 ≥ 50% were required for enrollment. Socio-economic deprivation was defined by an EPICES (Evaluation de la Précarité et des Inégalités de santé dans les Centres d'Examens de Santé - Evaluation of Deprivation and Inequalities in Health Examination Centres) score ≥ 30.17 and patients were included if they performed the 6-month evaluation. The primary outcome was respiratory sequelae 6 months after ICU discharge, defined by at least one of the following criteria: forced vital capacity < 80% of theoretical value, diffusing capacity of the lung for carbon monoxide < 80% of theoretical value, oxygen desaturation during a 6-min walk test and fibrotic-like findings on chest computed tomography.Results: Among 401 analyzable patients, 160 (40%) were socio-economically deprived and 241 (60%) non-deprived; 319 (80%) patients had respiratory sequelae 6 months after ICU discharge (81% vs 78%, deprived vs non-deprived, respectively). No significant effect of socio-economic status was identified on lung sequelae (odds ratio (OR), 1.19 [95% confidence interval (CI), 0.72-1.97]), even after adjustment for age, sex, most invasive respiratory support, obesity, most severe P/F ratio (adjusted OR, 1.02 [95% CI 0.57-1.83]).Conclusions: In COVID-19 ARDS survivors, socio-economic status had no significant influence on respiratory sequelae 6 months after ICU discharge.

---

Fichiers liés : s00134-023-07180-y.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/08/2023
• Auteurs : Justine Hugon-RodinCamille CarrièreSégolène ClaeyssensNathalie TrillotNicolas DrillaudChristine Biron-AndreaniCécile Lavenu-BombledAnna WielandClaire FlaujacNatalie StieltjesAurelien LebretonThomas BrungsAndrea HegglinMathieu FioreCéline DesconcloisValérie GayBrigitte Tardy-PoncetPhilippe BeurrierVirginie BarbayPierre ChamouniEmmanuel De MaistreTomas SimurdaAlessandro Casini
• Organismes : Maternité Port-Royal [CHU Cochin] Université Paris Descartes - Faculté de Médecine Centre Hospitalier Universitaire de Toulouse Centre Hospitalier Régional Universitaire [CHU Lille] Centre Hospitalier Universitaire de Nantes = Nantes University Hospital CHU Montpellier = Montpellier University Hospital GHU AP-HP. Université Paris Saclay Hémostase, Inflammation, Thrombose Centre Hospitalier de Versailles André Mignot Hôpital Cochin [AP-HP] Université Paris Cité CHU Clermont-Ferrand Unité de Nutrition Humaine Biologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases Hôpital Bicêtre [GHU AP-HP. Université Paris-Saclay, Le Kremlin-Bicêtre] Centre Hospitalier Métropole Savoie [Chambéry] Centre d'Investigation Clinique - Epidémiologie Clinique [CHU Saint-Etienne] Centre Hospitalier Universitaire d'Angers CHU Rouen CHU Rouen
• Publié dans Journal of Thrombosis and Haemostasis le 27/10/2020

---

Résumé : Background: Women with hereditary fibrinogen disorders (HFDs) seem to be at an increased risk of adverse obstetrical outcomes, but epidemiologic data are limited.Objectives: We aimed to determine the prevalence of pregnancy complications; the modalities and management of delivery; and the postpartum events in women with hypofibrinogenemia, dysfibrinogenemia, and hypodysfibrinogenemia.Methods: We conducted a retrospective and prospective multicentric international study.Results: A total of 425 pregnancies were investigated from 159 women (49, 95, and 15 cases of hypofibrinogenemia, dysfibrinogenemia, and hypodysfibrinogenemia, respectively). Overall, only 55 (12.9%) pregnancies resulted in an early miscarriage, 3 (0.7%) resulted in a late miscarriage, and 4 (0.9%) resulted in an intrauterine fetal death. The prevalence of live birth was similar among the types of HFDs (P = .31). Obstetrical complications were observed in 54 (17.3%) live birth pregnancies, including vaginal bleeding (14, 4.4%), retroplacental hematoma (13, 4.1%), and thrombosis (4, 1.3%). Most deliveries were spontaneous (218, 74.1%) with a vaginal noninstrumental delivery (195, 63.3%). A neuraxial anesthesia was performed in 116 (40.4%) pregnancies, whereas general or no anesthesia was performed in 71 (16.6%) and 129 (44.9%) pregnancies, respectively. A fibrinogen infusion was administered in 28 (8.9%) deliveries. Postpartum hemorrhages were observed in 62 (19.9%) pregnancies. Postpartum venous thrombotic events occurred in 5 (1.6%) pregnancies. Women with hypofibrinogenemia were at an increased risk of bleeding during the pregnancy (P = .04).Conclusion: Compared with European epidemiologic data, we did not observe a greater frequency of miscarriage, while retroplacental hematoma, postpartum hemorrhage, and thrombosis were more frequent. Delivery was often performed without locoregional anesthesia. Our findings highlight the urgent need for guidance on the management of pregnancy in HFDs.

---

Source

---

• Type de publi. : Chapître d'ouvrage
• Date de publi. : 01/08/2023
• Auteurs : M.-F. Corio-CostetDidier AndrivonJean-Noël AubertotMarc BardinMarie-Noëlle BrissetAgnes CalonnecMarc DufrêneSéverin HattChristophe Le MayPierre LerouxDidier MerdinogluPhilippe C. NicotPhilippe ReignaultPatrice ReyIvan SacheAli SiahLaurent ThibaultFlorence ValAnne-Sophie Walker
• Organismes : Santé et agroécologie du vignoble Institut de Génétique, Environnement et Protection des Plantes AGroécologie, Innovations, teRritoires Unité de Pathologie Végétale Unité de recherche Pathologie végétale et phytobactériologie Santé et agroécologie du vignoble Gembloux Agro-Bio Tech., Biodiversity and Landscape Unit Université de Liège = University of Liège = Universiteit van Luik = Universität Lüttich Institut de Génétique, Environnement et Protection des Plantes Littérature et poétique comparées Santé de la vigne et qualité du vin Unité de Pathologie Végétale Unité de Chimie Environnementale et Interactions sur le Vivant Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail Santé et agroécologie du vignoble AgroParisTech JUNIA BioEcoAgro - UMR transfrontalière INRAE 1158 BioEcoAgro - Equipe 5 - Specialized Metabolites of Plant Origin Institut Agro Rennes Angers BIOlogie et GEstion des Risques en agriculture

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/08/2023
• Auteurs : Julien AdamNolwenn Le StangArnaud UguenCécile BadoualMarie-Pierre ChenardSylvie LantuéjoulAurélie Maran-GonzalezYves-Marie RobinPhilippe RochaixJean-Christophe SabourinIsabelle SoubeyranNathalie SturmMagali SvrcekAnne Vincent-SalomonNina Radosevic-RobinFrédérique Penault-Llorca
• Organismes : Immunologie intégrative des tumeurs et immunothérapie des cancers Groupe Hospitalier Paris Saint-Joseph Centre Léon Bérard [Lyon] Registre général des cancers de la région Poitou-Charentes Centre Hospitalier Régional Universitaire de Brest Lymphocytes B, Autoimmunité et Immunothérapies Hôpital Européen Georges Pompidou [APHP] Hôpitaux Universitaires de Strasbourg Centre Léon Bérard [Lyon] CHU Montpellier = Montpellier University Hospital Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] Institut Universitaire du Cancer de Toulouse - Oncopole Département de Pathologie [CHU Rouen] Institut Bergonié [Bordeaux] Institut de Biologie et de Pathologie [CHU Grenoble] CHU Saint-Antoine [AP-HP] Département de Pathologie [Curie] Imagerie Moléculaire et Stratégies Théranostiques Centre Jean Perrin [Clermont-Ferrand] Imagerie Moléculaire et Stratégies Théranostiques Centre Jean Perrin [Clermont-Ferrand]
• Publié dans Modern Pathology le 23/10/2020

---

Résumé : Pan-Trk immunohistochemistry has been described as a screening test for the detection of NTRK fusions in a broad spectrum of tumor types. However, pan-Trk testing in the clinical setting may be limited by many factors, including analytical parameters such as clones, platforms, and protocols used. This study aimed to harmonize pan-Trk testing using various clones and immunohistochemical (IHC) platforms and to evaluate the level of analytical variability across pathology laboratories. We developed several IHC pan-Trk assays using clones EPR17341 (Abcam) and A7H6R (Cell Signaling Technology) on Ventana/Roche, Agilent, and Leica platforms. To compare them, we sent unstained sections of a tissue microarray containing 9 cases with NTRK3 fusions to participating laboratories, to perform staining on Ventana/Roche (10 centers), Agilent (4 centers), and Leica (3 centers) platforms. A ready-to-use pan-Trk IVD assay (Ventana/Roche) was also performed in 3 centers. All slides were centrally and blindly reviewed for the percentage of stained tumor cells. Laboratory-developed tests with clone EPR17341 were able to detect pan-Trk protein expression in all cases, whereas lower rates of positivity were observed with clone A7H6R. Moderate to strong variability of the positive cases rate was observed with both antibodies in each IHC platforms type and each of the positivity cut points evaluated (≥1%, ≥10%, and ≥50% of stained tumor cells). The rate of false-negative cases was lower when pan-Trk staining was assessed with the lowest positivity threshold (≥1%). In conclusion, most evaluated pan-Trk IHC laboratory-developed tests were able to detect NTRK3-fusion proteins; however, a significant analytical variability was observed between antibodies, platforms, and centers.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/08/2023
• Auteurs : Mikael CohenOcéane Thomel-RocchiAksel SivaDarin OkudaRana KarabudakHüsnü EfendiMurat TerziClarisse Carra DallièreFrançoise Durand-DubiefEric ThouvenotJonathan CironHélène ZéphirBertrand BourreOlivier CasezJérôme de SèzeThibault MoreauJean-Philippe NeauDaniel PelletierOrhun KantarciMelih TutuncuNathalie DeracheCaroline BensaCeline LouapreJeanne BenoitCassandre Landes-ChâteauChristine Lebrun-FrenayChristina AzevedoNaila MakhaniSedat ŞenUgur Uygunoglu
• Organismes : Unité de Recherche Clinique Côte d’Azur Service de Neurologie [CHU Nice] Service de Neurologie [CHU Nice] Cerrahpasa Faculty of Medicine University of Texas Southwestern Medical Center Faculty of Medicine [Hacettepe University] Kocaeli University [Turkey] Ondokuz Mayis University Département de Neurologie [Hôpital Gui de Chauliac - CHU Montpellier] Service de neurologie fonctionnelle et d'épileptologie [Hôpital Pierre Wertheimer-HCL] Montpellier GenomiX Département Neurologie [CHU Toulouse] Institut Toulousain des Maladies Infectieuses et Inflammatoires Lille Neurosciences & Cognition - U 1172 Service de neurologie [Rouen] CHU de Grenoble-Alpes - Centre Hospitalier Universitaire CHU Grenoble Translational Research in Autoimmunity and Inflammation Group CIC Strasbourg Service de Neurologie générale, vasculaire et dégénérative (CHU de Dijon) Service de neurologie [CHU de Poitiers] University of Southern California Mayo Clinic [Rochester] Cerrahpasa Faculty of Medicine Service de Neurologie [CHU Caen] Service de neurologie [Hôpital Fondation Adolphe de Rothschild] Centre d'investigation clinique Neurosciences [CHU Pitié Salpêtrière] Unité de Recherche Clinique Côte d’Azur Service de Neurologie [CHU Nice] Unité de Recherche Clinique Côte d’Azur Service de Neurologie [CHU Nice] Unité de Recherche Clinique Côte d’Azur Service de Neurologie [CHU Nice] University of Southern California Yale University [New Haven] Ondokuz Mayis University Cerrahpasa Faculty of Medicine
• Publié dans Multiple Sclerosis Journal le 31/10/2020

---

Résumé : Background: Vaccination in patients with multiple sclerosis (MS) treated with immunosuppressive drugs is highly recommended. Regarding COVID-19 vaccination, no specific concern has been raised. Objectives: We aimed to evaluate if COVID-19 vaccination or infection increased the risk of disease activity, either radiological or clinical, with conversion to MS in a cohort of people with a radiologically isolated syndrome (RIS). Methods: This multicentric observational study analyzed patients in the RIS Consortium cohort during the pandemic between January 2020 and December 2022. We compared the occurrence of disease activity in patients according to their vaccination status. The same analysis was conducted by comparing patients' history of COVID-19 infection. Results: No difference was found concerning clinical conversion to MS in the vaccinated versus unvaccinated group (6.7% vs 8.5%, p > 0.9). The rate of disease activity was not statistically different (13.6% and 7.4%, respectively, p = 0.54). The clinical conversion rate to MS was not significantly different in patients with a documented COVID-19 infection versus non-infected patients. Conclusion: Our study suggests that COVID-19 infection or immunization in RIS individuals does not increase the risk of disease activity. Our results support that COVID-19 vaccination can be safely proposed and repeated for these subjects.

---

Source